MetaADEDB 2.0 @ LMMD
Deoxycholic Acid
(KXGVEGMKQFWNSR-LLQZFEROSA-N)
Structure
SMILES
O[C@@H]1CC[C@]2([C@@H](C1)CC[C@@H]1[C@@H]2C[C@H](O)[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)O)C)C)C
Type(s)
Approved
ATC code(s)
D11AX24
Molecular Formula:
C24H40O4
Molecular Weight:
392.572
Log P:
4.4779
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
3
TPSA:
77.76
CAS Number(s):
83-44-3; 115349-14-9
Synonym(s)
1.
Deoxycholic Acid
2.
Deoxycholate
3.
Desoxycholic Acid
4.
Choleic Acid
5.
Deoxycholic Acid, 12beta-Isomer
6.
Deoxycholic Acid, 3beta-Isomer
7.
Deoxycholic Acid, 5alpha-Isomer
8.
Deoxycholic Acid, Disodium Salt
9.
Deoxycholic Acid, Magnesium (2:1) Salt
10.
Deoxycholic Acid, Monoammonium Salt
11.
Deoxycholic Acid, Monopotassium Salt
12.
Deoxycholic Acid, Monosodium Salt
13.
Deoxycholic Acid, Sodium Salt, 12beta-Isomer
14.
Dihydroxycholanoic Acid
15.
Lagodeoxycholic Acid
16.
Sodium Deoxycholate
17.
12beta-Isomer Deoxycholic Acid
18.
3beta-Isomer Deoxycholic Acid
19.
5alpha-Isomer Deoxycholic Acid
20.
Acid, 5alpha-Isomer Deoxycholic
21.
Acid, Choleic
22.
Acid, Deoxycholic
23.
Acid, Desoxycholic
24.
Acid, Dihydroxycholanoic
25.
Acid, Lagodeoxycholic
26.
Deoxycholate, Sodium
27.
Deoxycholic Acid, 12beta Isomer
28.
Deoxycholic Acid, 3beta Isomer
29.
Deoxycholic Acid, 5alpha Isomer
External Link(s)
MeSHD003840
PubChem Compound222528
BindingDB50375599
ChEBI28834
CHEMBLCHEMBL406393
DrugBankDB03619
DrugCentral4988
IUPHAR/BPS Guide to PHARMACOLOGY610
KEGGcpd:C04483
dr:D10781
Therapeutic Target DatabaseD02PQB
ZINC3914810
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 148US FAERS
2SwellingFAERS: 108US FAERS
3Injection site painFAERS: 92US FAERS
4Injection site noduleFAERS: 76US FAERS
5Nerve injuryFAERS: 56US FAERS
6Facial ParesisFAERS: 54US FAERS
7Injection site massFAERS: 46US FAERS
8Injection site erythemaFAERS: 41US FAERS
9Injection site bruisingFAERS: 40US FAERS
10Facial asymmetryFAERS: 30US FAERS
11AlopeciaFAERS: 23US FAERS
12PainFAERS: 23US FAERS
13ErythemaFAERS: 21US FAERS
14Wrong technique in product usage processFAERS: 21US FAERS
15IndurationFAERS: 17US FAERS
16Neck PainFAERS: 17US FAERS
17Injection site ulcerFAERS: 16US FAERS
18NoduleFAERS: 16US FAERS
19DizzinessFAERS: 15US FAERS
20Oropharyngeal painFAERS: 15US FAERS
21Skin UlcerFAERS: 15US FAERS
22Injection site discomfortFAERS: 13US FAERS
23HeadacheFAERS: 12US FAERS
24PallorFAERS: 12US FAERS
25UrticariaFAERS: 12US FAERS
26Facial paralysisFAERS: 11US FAERS
27Feeling abnormalFAERS: 11US FAERS
28Injection site necrosisFAERS: 11US FAERS
29Injection site warmthFAERS: 11US FAERS
30Weight decreasedFAERS: 11US FAERS
31Injection site inflammationFAERS: 10US FAERS
32Product administered at inappropriate siteFAERS: 10US FAERS
33NauseaFAERS: 9US FAERS
34Administration site indurationFAERS: 8US FAERS
35LymphadenopathyFAERS: 8US FAERS
36ScabFAERS: 8US FAERS
37Wrong drug administeredFAERS: 8US FAERS
38DiscomfortFAERS: 7US FAERS
39Facial PainFAERS: 7US FAERS
40Injection site scabFAERS: 7US FAERS
41ToothacheFAERS: 7US FAERS
42Vascular occlusionFAERS: 7US FAERS
43Application site swellingFAERS: 6US FAERS
44Expired product administeredFAERS: 6US FAERS
45Incorrect route of drug administrationFAERS: 6US FAERS
46Incorrect route of product administrationFAERS: 6US FAERS
47Pain of skinFAERS: 6US FAERS
48PruritusFAERS: 6US FAERS
49Rash erythematousFAERS: 6US FAERS
50VomitingFAERS: 6US FAERS
51AcneFAERS: 5US FAERS
52Cerebrovascular accidentFAERS: 5US FAERS
53Dry skinFAERS: 5US FAERS
54DysarthriaFAERS: 5US FAERS
55Injection site scarFAERS: 5US FAERS
56Skin WrinklingFAERS: 5US FAERS
57Skin tightnessFAERS: 5US FAERS
58Accidental exposure to productFAERS: 4US FAERS
59Alopecia AreataFAERS: 4US FAERS
60Drug ineffective for unapproved indicationFAERS: 4US FAERS
61Excessive skinFAERS: 4US FAERS
62HypersensitivityFAERS: 4US FAERS
63InflammationFAERS: 4US FAERS
64Injection site pruritusFAERS: 4US FAERS
65Injection site vesiclesFAERS: 4US FAERS
66Musculoskeletal stiffnessFAERS: 4US FAERS
67Occupational exposure to productFAERS: 4US FAERS
68Skin irritationFAERS: 4US FAERS
69Skin necrosisFAERS: 4US FAERS
70Thermal burnFAERS: 4US FAERS
71Adverse eventFAERS: 3US FAERS
72Application site alopeciaFAERS: 3US FAERS
73CalcinosisFAERS: 3US FAERS
74Chest discomfortFAERS: 3US FAERS
75ChillsFAERS: 3US FAERS
76Drug administered at inappropriate siteFAERS: 3US FAERS
77DysgeusiaFAERS: 3US FAERS
78DysphoniaFAERS: 3US FAERS
79Eye irritationFAERS: 3US FAERS
80Injection Site ReactionFAERS: 3US FAERS
81Injection site atrophyFAERS: 3US FAERS
82Injection site cystFAERS: 3US FAERS
83Injection site urticariaFAERS: 3US FAERS
84Joint stiffnessFAERS: 3US FAERS
85Lip exfoliationFAERS: 3US FAERS
86MalaiseFAERS: 3US FAERS
87Mouth swellingFAERS: 3US FAERS
88PresyncopeFAERS: 3US FAERS
89Skin IndurationFAERS: 3US FAERS
90Skin lesionFAERS: 3US FAERS
91UlcerFAERS: 3US FAERS
92VertigoFAERS: 3US FAERS
93AbscessFAERS: 2US FAERS
94Administration site abscessFAERS: 2US FAERS
95Administration site necrosisFAERS: 2US FAERS
96AmnesiaFAERS: 2US FAERS
97AnxietyFAERS: 2US FAERS
98Application site noduleFAERS: 2US FAERS
99Application site painFAERS: 2US FAERS
100Chemical injuryFAERS: 2US FAERS
101Chest PainFAERS: 2US FAERS
102ChloasmaFAERS: 2US FAERS
103Cold sweatFAERS: 2US FAERS
104Counterfeit product administeredFAERS: 2US FAERS
105DeformityFAERS: 2US FAERS
106Drug effect incompleteFAERS: 2US FAERS
107EmbolismFAERS: 2US FAERS
108Emotional distressFAERS: 2US FAERS
109EncephalitisFAERS: 2US FAERS
110Feeling ColdFAERS: 2US FAERS
111FlushingFAERS: 2US FAERS
112FrostbiteFAERS: 2US FAERS
113Gingival RecessionFAERS: 2US FAERS
114Incorrect dose administeredFAERS: 2US FAERS
115InfectionFAERS: 2US FAERS
116Injection site alopeciaFAERS: 2US FAERS
117Injection site hypersensitivityFAERS: 2US FAERS
118Injection site hypertrophyFAERS: 2US FAERS
119Injection site infectionFAERS: 2US FAERS
120Injection site pallorFAERS: 2US FAERS
121Lip swellingFAERS: 2US FAERS
122Muscle tightnessFAERS: 2US FAERS
123Musculoskeletal discomfortFAERS: 2US FAERS
124NecrosisFAERS: 221362627CTD
US FAERS
125Nuchal RigidityFAERS: 2US FAERS
126Oral painFAERS: 2US FAERS
127Oral pustuleFAERS: 2US FAERS
128PalpitationsFAERS: 2US FAERS
129Procedural complicationFAERS: 2US FAERS
130SepsisFAERS: 2US FAERS
131Soft tissue massFAERS: 2US FAERS
132Trigeminal palsyFAERS: 2US FAERS
133Visual ImpairmentFAERS: 2US FAERS
134Vulvovaginal pruritusFAERS: 2US FAERS
135Administration site discomfortFAERS: 1US FAERS
136Administration site erythemaFAERS: 1US FAERS
137Administration site extravasationFAERS: 1US FAERS
138Administration site scabFAERS: 1US FAERS
139Administration site swellingFAERS: 1US FAERS
140Administration site warmthFAERS: 1US FAERS
141AgeusiaFAERS: 1US FAERS
142AphasiaFAERS: 1US FAERS
143Application site indurationFAERS: 1US FAERS
144Application site movement impairmentFAERS: 1US FAERS
145Application site plaqueFAERS: 1US FAERS
146Application site vesiclesFAERS: 1US FAERS
147Arterial InjuryFAERS: 1US FAERS
148ArteriosclerosisFAERS: 1US FAERS
149ArthralgiaFAERS: 1US FAERS
150AstheniaFAERS: 1US FAERS
151Back PainFAERS: 1US FAERS
152Blood blisterFAERS: 1US FAERS
153Blood ketone body increasedFAERS: 1US FAERS
154Blood triglycerides increasedFAERS: 1US FAERS
155Bowel movement irregularityFAERS: 1US FAERS
156Burning sensationFAERS: 1US FAERS
157Chemical burn of skinFAERS: 1US FAERS
158Choking sensationFAERS: 1US FAERS
159Circumstance or information capable of leading to medication errorFAERS: 1US FAERS
160Cluster HeadacheFAERS: 1US FAERS
161ConstipationFAERS: 1US FAERS
162Cutis LaxaFAERS: 1US FAERS
163DermatitisFAERS: 1US FAERS
164DisorientationFAERS: 1US FAERS
165Drug administration errorFAERS: 1US FAERS
166Ear discomfortFAERS: 1US FAERS
167Fat necrosisFAERS: 1US FAERS
168Fat redistributionFAERS: 1US FAERS
169Gait inabilityFAERS: 1US FAERS
170General physical condition abnormalFAERS: 1US FAERS
171Gingival discomfortFAERS: 1US FAERS
172GranulomaFAERS: 1US FAERS
173Guillain-Barre SyndromeFAERS: 1US FAERS
174Head discomfortFAERS: 1US FAERS
175HyperplasiaFAERS: 18095246CTD
US FAERS
176HypertrophyFAERS: 1US FAERS
177HypothyroidismFAERS: 1US FAERS
178HypotrichosisFAERS: 1US FAERS
179Iatrogenic injuryFAERS: 1US FAERS
180Impaired driving abilityFAERS: 1US FAERS
181Impaired work abilityFAERS: 1US FAERS
182ImpetigoFAERS: 1US FAERS
183Inappropriate schedule of product administrationFAERS: 1US FAERS
184Injection site abscessFAERS: 1US FAERS
185Injection site cellulitisFAERS: 1US FAERS
186Injection site deformationFAERS: 1US FAERS
187Injection site dermatitisFAERS: 1US FAERS
188Injection site dischargeFAERS: 1US FAERS
189Injection site exfoliationFAERS: 1US FAERS
190Injection site fibrosisFAERS: 1US FAERS
191Injection site indentationFAERS: 1US FAERS
192Injection site irritationFAERS: 1US FAERS
193Injection site joint swellingFAERS: 1US FAERS
194Injection site nerve damageFAERS: 1US FAERS
195Intentional product misuseFAERS: 1US FAERS
196Irritable Bowel SyndromeFAERS: 1US FAERS
197Joint swellingFAERS: 1US FAERS
198LacerationFAERS: 1US FAERS
199LeukodermaFAERS: 1US FAERS
200Limb discomfortFAERS: 1US FAERS
201LipoatrophyFAERS: 1US FAERS
202LipohypertrophyFAERS: 1US FAERS
203LipomaFAERS: 1US FAERS
204Mastication disorderFAERS: 1US FAERS
205Medication ErrorFAERS: 1US FAERS
206Memory impairmentFAERS: 1US FAERS
207Multifocal motor neuropathyFAERS: 1US FAERS
208Musculoskeletal PainFAERS: 1US FAERS
209Musculoskeletal chest painFAERS: 1US FAERS
210MyalgiaFAERS: 1US FAERS
211NasopharyngitisFAERS: 1US FAERS
212Necrosis of arteryFAERS: 1US FAERS
213NeuralgiaFAERS: 1US FAERS
214Oral pruritusFAERS: 1US FAERS
215Oropharyngeal blisteringFAERS: 1US FAERS
216Oropharyngeal discomfortFAERS: 1US FAERS
217OverdoseFAERS: 1US FAERS
218Peripheral swellingFAERS: 1US FAERS
219Post inflammatory pigmentation changeFAERS: 1US FAERS
220PregnancyFAERS: 1US FAERS
221Product administration errorFAERS: 1US FAERS
222Product counterfeitFAERS: 1US FAERS
223Product label confusionFAERS: 1US FAERS
224Product packaging quantity issueFAERS: 1US FAERS
225Product use issueFAERS: 1US FAERS
226Productive CoughFAERS: 1US FAERS
227Propionibacterium infectionFAERS: 1US FAERS
228Pyoderma GangrenosumFAERS: 1US FAERS
229Reflux laryngitisFAERS: 1US FAERS
230Retinal DetachmentFAERS: 1US FAERS
231SeromaFAERS: 1US FAERS
232Skin ErosionFAERS: 1US FAERS
233Skin hypertrophyFAERS: 1US FAERS
234Skin indentationFAERS: 1US FAERS
235Skin lacerationFAERS: 1US FAERS
236Skin texture abnormalFAERS: 1US FAERS
237Soft tissue necrosisFAERS: 1US FAERS
238Supraventricular tachycardiaFAERS: 1US FAERS
239SyncopeFAERS: 1US FAERS
240Tendon discomfortFAERS: 1US FAERS
241Thyroid NeoplasmFAERS: 1US FAERS
242TinnitusFAERS: 1US FAERS
243Tissue injuryFAERS: 1US FAERS
244TonsillitisFAERS: 1US FAERS
245TremorFAERS: 1US FAERS
246TrismusFAERS: 1US FAERS
247Venous InjuryFAERS: 1US FAERS
248Wrong product administeredFAERS: 1US FAERS
249Aberrant Crypt Foci12636105CTD
250Brain Injuries17188501CTD
251Chemical and Drug Induced Liver Injury

View details

CTD
252Colonic Neoplasms16213893
18444174
CTD
253Gliosis17188501CTD
254Liver Neoplasms, Experimental6150873
6150874
CTD
255Liver neoplasms1641875CTD
256Movement Disorders17188501CTD
257Precancerous Conditions1974829
8095246
8593453
CTD
258Stomach Neoplasms2704366CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.